- Follow up continues for the primary endpoint of 2 year MFS in ITT: 81.7% are so far w/o M1 dz
- 77% of patients on active surveillance are alive, without M1 dz and with their bladder intact
- 65% of patients on active surveillance have had some form of recurrence: 9/17 being NMIBC with bladder still intact
- 11.5% of patients on active surveillance have had M1 dz vs. 23.6% in those w/o mut
- HCRN GU16 257 and A031701 are ongoing
- Risk adapted bladder preservation is NOT a standard of care
Publications
A Phase II Trial of Risk Enabled Therapy After Initiating Neoadjuvant Chemotherapy for Bladder Cancer (RETAIN BLADDER) Interim analysis
– Caris Life Sciences